Listar INIBIC-ICATC - Artigos por título
Mostrando ítems 101-120 de 176
-
Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure
(Elsevier, 2023-11-15)[Abstract] Aims: Aims were to evaluate (1) reclassification of patients from heart failure with mildly reduced (HFmrEF) to reduced (HFrEF) ejection fraction when an EF = 40% was considered as HFrEF, (2) role of EF digit ... -
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
(Wolters Kluwer, 2020-07)[Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ... -
Light Chain and Transthyretin Cardiac Amyloidosis: Clinical Characteristics, Natural History and Prognostic Factors
(Elsevier, 2021-03-13)[Abstract] Introduction and objectives. Light-chain amyloidosis (AL-CA) and transthyretin amyloidosis (ATTR-CA) are the most common types of cardiac amyloidosis (CA). We sought to study the clinical characteristics and ... -
Malignancy following heart transplantation: differences in incidence and prognosis between sexes – a multicenter cohort study
(Wiley Online Library, 2021-03-12)[Abstract] Male patients are at increased risk for developing malignancy postheart transplantation (HT); however, real incidence and prognosis in both genders remain unknown. The aim of this study was to assess differences ... -
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes
(Elsevier, 2021-08-04)[Abstract] Background: The Molecular Microscope (MMDx) system classifies heart transplant endomyocardial biopsies as No-rejection (NR), Early-injury, T cell-mediated (TCMR), antibody-mediated (ABMR), mixed, and possible ... -
Mitochondrial DNA haplogroup H as a risk factor for idiopathic dilated cardiomyopathy in Spanish population
(Elsevier, 2013-03-23)[Abstract] Idiopathic dilated cardiomyopathy (IDC) is a structural heart disease with strong genetic background. The different single nucleotide polymorphisms (SNPs) that constitute mitochondrial haplogroups could play an ... -
Mitochondrial Pyruvate Carrier Abundance Mediates Pathological Cardiac Hypertrophy
(Springer Nature, 2020-10-26)[Abstract] Cardiomyocytes rely on metabolic substrates, not only to fuel cardiac output, but also for growth and remodelling during stress. Here we show that mitochondrial pyruvate carrier (MPC) abundance mediates ... -
Molecular states associated with dysfunction and graft loss in heart transplants
(Elsevier, 2023-11-30)[Abstract] Background: We explored the changes in gene expression correlating with dysfunction and graft failure in endomyocardial biopsies. Methods: Genome-wide microarrays (19,462 genes) were used to define mRNA ... -
Multi-omics approach reveals prebiotic and potential antioxidant effects of essential oils from the mediterranean diet on cardiometabolic disorder using humanized gnotobiotic mice
(MDPI, 2023-08-20)[Abstract] Essential oils sourced from herbs commonly used in the Mediterranean diet have demonstrated advantageous attributes as nutraceuticals and prebiotics within a model of severe cardiometabolic disorder. The primary ... -
Multilevel factors are associated with immunosuppressant nonadherence in heart transplant recipients: the international BRIGHT study
(Elsevier, 2017-12-05)[Abstract] Factors at the level of family/healthcare worker, organization, and system are neglected in medication nonadherence research in heart transplantation (HTx). The 4-continent, 11-country cross-sectional Building ... -
Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension
(Oxford Academic, 2022-12-21) -
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)[Abstract] Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ... -
Oxygen therapy and palliative care in patients with heart failure. Response
(Elsevier, 2020-05-04) -
Perfiles analíticos pre-configurados en insuficiencia cardiaca: implementación y uso en el Sistema Nacional de Salud Español
(De Gruyter, 2022-03-07)[Resumen] Objetivos. El uso de los perfiles analíticos pre-configurados (PAPs) en el contexto de la insuficiencia cardíaca (IC) podría ayudar a realizar un mejor manejo clínico y gestión eficiente del paciente. Los objetivos ... -
Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients
(BioMed Central, 2015-10-09)[Abstract] Background. A single non-invasive gene expression profiling (GEP) test (AlloMap®) is often used to discriminate if a heart transplant recipient is at a low risk of acute cellular rejection at time of testing. ... -
Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure long-term registry
(Elsevier, 2018-06)[Abstract] Objectives. This study compared the performance of major heart failure (HF) risk models in predicting mortality and examined their utilization using data from a contemporary multinational registry. Background. ... -
Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival
(Willey, 2021-01-19)[Abstract] Background. The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for ... -
Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection
(Elsevier, 2017-07-15)[Abstract] Background. Heart transplantation (HT) is a life-saving treatment for patients with end-stage heart failure. One of the main problems after HT is the humoral response termed antibody-mediated rejection (AMR). ...